Linked Life Data

14986065

Source:http://linkedlifedata.com/resource/pubmed/id/14986065

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14986065rdf:typepubmed:Citationlld:pubmed
pubmed-article:14986065lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0346421lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0007682lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0544452lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0935989lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0205197lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C0231242lld:lifeskim
pubmed-article:14986065lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:14986065pubmed:issue7lld:pubmed
pubmed-article:14986065pubmed:dateCreated2004-6-1lld:pubmed
pubmed-article:14986065pubmed:abstractTextMany cases of hypereosinophilia, formerly classified as hypereosinophilic syndrome, can now be characterized as chronic eosinophilic leukemia (CEL) based on the demonstration of characteristic genetic markers indicating clonality of hematopoiesis. Here we report on a 33-year-old male patient with central nervous system manifestations of CEL and an excellent response to low-dose imatinib (Glivec). Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib.lld:pubmed
pubmed-article:14986065pubmed:languageenglld:pubmed
pubmed-article:14986065pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:citationSubsetIMlld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14986065pubmed:statusMEDLINElld:pubmed
pubmed-article:14986065pubmed:monthJullld:pubmed
pubmed-article:14986065pubmed:issn0939-5555lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:BauerHeidiHlld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:HochhausAndre...lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:ReiterAndreas...lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:Märker-Herman...lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:FrickhofenNor...lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:WalzChristoph...lld:pubmed
pubmed-article:14986065pubmed:authorpubmed-author:JungBerndBlld:pubmed
pubmed-article:14986065pubmed:issnTypePrintlld:pubmed
pubmed-article:14986065pubmed:volume83lld:pubmed
pubmed-article:14986065pubmed:ownerNLMlld:pubmed
pubmed-article:14986065pubmed:authorsCompleteYlld:pubmed
pubmed-article:14986065pubmed:pagination477-80lld:pubmed
pubmed-article:14986065pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:meshHeadingpubmed-meshheading:14986065...lld:pubmed
pubmed-article:14986065pubmed:year2004lld:pubmed
pubmed-article:14986065pubmed:articleTitleComplete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.lld:pubmed
pubmed-article:14986065pubmed:affiliationDepartment of Hematology/Oncology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany. norbert.frickhofen@hsk-wiesbaden.delld:pubmed
pubmed-article:14986065pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14986065pubmed:publicationTypeCase Reportslld:pubmed